Trial Profile

An Open, Single-arm, Multi-center Phase II Clinical Study of ENVAFOLIMAB Single-agent Treatment in Patients With Advanced Solid Tumors

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 26 Aug 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Envafolimab (Primary)
Indications Bladder cancer; Cervical cancer; Cholangiocarcinoma; Colorectal cancer; Endometrial cancer; Follicular lymphoma; Gastric cancer; Head and neck cancer; Malignant melanoma; Merkel cell carcinoma; Neuroendocrine tumours; Ovarian cancer; Salivary gland cancer; Small cell lung cancer; Solid tumours; Squamous cell cancer; Thyroid cancer; Vulvovaginal cancer
Focus Therapeutic Use
Sponsors 3D Medicines

01 Apr 2024 Planned number of patients changed from 200 to 126.
01 Apr 2024 Planned End Date changed from 30 Apr 2024 to 30 Aug 2028.
01 Apr 2024 Planned primary completion date changed from 30 Apr 2024 to 30 Aug 2027.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com